Weekly docetaxel, estramustine phosphate and low-dose dexamethasone in Japanese men with hormone refractory prostate cancer

Authors :: M. Morita
H. Yoshida
K. Fuji
T. Fukagai
Source :: Journal of Clinical Oncology. 23:4789-4789
Publication Year :: 2005
Publisher :: American Society of Clinical Oncology (ASCO), 2005.
Abstract: 4789 Background: Recently, docetaxel have shown promising clinical results in patients with hormone-refractory prostate cancer (HRPC). However, their optimal treatment schedule has not been establi...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Schedule
business.industry
Docetaxel/estramustine
Low dose
medicine.disease
Hormone refractory prostate cancer
Prostate cancer
Docetaxel
Internal medicine
Medicine
In patient
business
Dexamethasone
medicine.drug

Full Text Access

Tools